From bedside to bench and back: discovery of a novel missense
 variant in NLRP3 causing atypical CAPS with hearing loss as the
 primary presentation, responsive to anti-IL-1 therapy

Merav Birk-Bachar<sup>1</sup>, Hadar Cohen<sup>2</sup>, Efrat Sofrin-Drucker<sup>3,6,7</sup>, Nesia Kropach-Gilad<sup>3,6,7</sup>,
Naama Orenstein<sup>3,6,7</sup>, Gabriel Lidzbarsky<sup>6</sup>, Liora Kornreich<sup>4,7</sup>, Rotem Tal<sup>1,7</sup>, Gil
Amarilyo<sup>1,7</sup>, Yoel Levinsky<sup>1,7</sup>, Meirav Sokolov<sup>5,7</sup>, Eyal Raveh<sup>5,7</sup>, Motti Gerlic<sup>2<sup>+</sup></sup>, Liora
Harel<sup>1,7<sup>+</sup></sup>

- 8 <sup>†</sup>These authors contributed equally to this work and share senior authorship
- 9
- <sup>1</sup> Pediatric Rheumatology Unit, Schneider Children's Medical Center of Israel, Petach-Tikva,
   Israel
- <sup>2</sup> Department of Clinical Microbiology and Immunology, Sackler Faculty of Medicine, Tel
   Aviv University, Tel-Aviv, Israel
- <sup>3</sup> Genetics Unit, Schneider Children's Medical Center of Israel, Petach-Tikva, Israel
- <sup>4</sup> Pediatric Imaging Unit, Schneider Children's Medical Center of Israel, Petach-Tikva, Israel
- <sup>5</sup> Pediatric Ear Nose and Throat Unit, Schneider Children's Medical Center of Israel, Petach Tikva, Israel
- <sup>6</sup> Recanati Genetic Institute, Rabin Medical Center-Beilinson Hospital, Petach Tikva, Israel
- <sup>7</sup> Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel
- 20 **\*Correspondence;**
- 21 Dr. Merav Birk-Bachar Merav.birk@gmail.com
- 22 Associate Prof. Motti Gerlic mgerlic@tauex.tau.ac.il
- 23 Prof. Liora Harel liorahar@clalit.org.il
- 24
- 25
- 26 Number of words in manuscript: 4308 Number of figures: 6
- 27
- 28 Keywords: Inflammasome, caspase-1, deafness, anakinra, sensori-neural, 29 autoinflammation

#### 30 ABSTRACT

31 Cryopyrin-associated periodic syndromes (CAPS) also known as NLRP3-associated 32 auto-inflammatory diseases, are a spectrum of rare auto-inflammatory diseases caused by 33 gain-of-function mutations in the NLRP3 gene, resulting in inflammasome hyper-activation and 34 dysregulated release of Interleukin-1 $\beta$  (IL-1 $\beta$ ). Many patients with CAPS develop progressive sensorineural hearing loss (SNHL) due to cochlear auto-inflammation which, in rare cases, 35 may be the sole manifestation. This study was undertaken to establish the suspected diagnosis 36 37 of CAPS in a family presenting autosomal dominant progressive/acute SNHL and a novel missense variant in the NLRP3 gene of unknown significance (NM 001079821:c.1790G>A, 38 39 p.Ser597Asn). To do so, we conducted an ex vivo functional assessment of the NLRP3 inflammasome in carries (n=10) and healthy family members (n=5). The assay revealed 40 hyper-activation of the inflammasome among carriers, supporting the hypothesis that this 41 missense variant is a pathogenic gain-of-function mutation. Administration of anti-IL-1 42 43 therapy resulted in a substantial clinical improvement among pediatric patients, who 44 exhibited near resolution of hearing impairment within 1-3 months of treatment. Our findings 45 highlight the crucial role of early diagnosis and treatment of hearing loss due to hyperactivation of the inflammasome with an anti-IL-1 agent in reversing cochlear damage. 46 47 Furthermore, our results suggest that high and ultrahigh frequency ranges need to be included in the auditory assessment to enable early detection of subclinical SNHL. Finally, 48 49 incorporating functional inflammasome assessment as part of the clinical evaluation could 50 establish the diagnosis in inconclusive cases.

#### 52 Introduction

53 The NLRP3 inflammasome[1] is an intracellular innate immune sensor expressed in 54 immune cells, including monocytes and macrophages. Gain-of-function mutations in the 55 NLRP3 gene lead to hyperactivation of the NLRP3 inflammasome, resulting in the 56 inappropriate release of inflammatory cytokines, including IL-1 $\beta$ , and causing a spectrum of 57 autosomal-dominant systemic autoinflammatory diseases called cryopyrin-associated periodic syndromes (CAPS) or NLRP3-associated autoinflammatory diseases (NLRP3-58 59 AIDs)[2,3]. The CAPS spectrum includes three classical clinical subtypes: neonatal-onset 60 multisystem inflammatory disease (NOMID, MIM 607115), Muckle-Wells syndrome (MWS, 61 MIM 191900), and familial cold autoinflammatory syndrome (FCAS, MIM 120100). The age 62 at onset, as well as the severity of symptoms, vary within this spectrum and include recurrent 63 fever, typical urticaria-like rash, headache, conjunctivitis, and arthralgia or arthritis.[3] Many 64 of these patients, particularly those with the more severe phenotypes, also develop 65 progressive sensorineural hearing loss (SNHL) due to cochlear auto-inflammation(Yamada et 66 al., 2022(. In rare cases, SNHL may be the primary finding, and it was suggested that cochlear auto-inflammation was caused by hyper-activation of the NLRP3 inflammasome in tissue-67 resident macrophage/monocyte-like cells[5,6]. 68

Inflammasomes are a group of cytosolic protein complexes located mainly in myeloid 69 70 lineage cells that are formed to mediate host immune responses to microbial infection and cellular damage [7]. The NLRP3 inflammasome activation process is dependent on a two-71 72 signal sequence. In the absence of either signal, the inflammasome remains inactive. The first 73 "priming" step, initiated by either pathogen-associated molecular pattern molecules 74 (PAMPs), danger-associated molecular patterns (DAMPs), or pro-inflammatory cytokines, 75 activates transcriptional factors NF- $\kappa$ B/AP1, resulting in the upregulation of inflammasome 76 components as pro-caspase-1 and pro-inflammatory cytokines (i.e., pro-IL-1 $\beta$  and pro-IL-18). 77 The second "activating" step, initiated by the recognition of either PAMPs or DAMPs, results 78 in the oligomerization of inflammasome protein components [8]. Inflammasome formation 79 then leads to auto-cleavage of caspases-1 and subsequent cleavage of gasdermin-D 80 (GSDMD), which tends to translocate to the outer membrane to form pores and subsequently 81 induce pyroptotic cell death. Inflammasome activation also cleaves pro-IL-1 $\beta$  and pro-IL-18 82 to their mature and active forms, which are then released through the GSDMD pores, creating 83 a proinflammatory cascade [9,10]. In the case of NLRP3 gain-of-function mutations, the threshold for inflammasome activation may be either impaired or totally lost, resulting in 84 85 inappropriate activation of the inflammasome. This hyperactivity is classically demonstrated ex-vivo by measuring levels of IL-1ß in supernatants of PBMCs, in response to NF-kB 86 87 stimulation alone (priming signal).

In this study, we present a family that initially presented with autosomal dominant SNHL and a novel variant in the NLRP3 gene of unknown significance, which did not meet CAPS classification criteria. By conducting an *ex-vivo* functional assessment of the NLRP3 inflammasome, which showed inflammasome hyperactivity, we strengthened the suspected diagnosis of CAPS. Finally, following this assessment, we applied an anti-IL-1 treatment that resulted in a rapid substantial clinical hearing improvement in young patients.

#### 94 **<u>Results</u>**

#### 95 Hearing loss as the main or sole presentation of CAPS

96 The proband, a two-year-old boy at the time of study initiation (III1), was initially 97 referred to the Pediatric Rheumatology Unit due to recurrent episodes of fever and was 98 eventually clinically diagnosed with PFAPA (periodic fever, aphthous stomatitis, pharyngitis, 99 and adenitis). Family history revealed six family members spanning three generations who 100 had previously been diagnosed with autosomal dominant, bilateral, progressive SNHL (Figure 1A, Table 1). The eldest (1<sup>st</sup> generation) and most severely affected patient was the 101 proband's >70-year-old grandmother (patient I4). She described progressive hearing loss 102 103 commencing at age 15-20, as well as two episodes of unilateral (left) acute sensorineural 104 hearing loss over the years that partially responded to steroid treatment (Figure 2). She 105 eventually underwent left cochlear implantation at age 50-55. In addition, she suffered from 106 infrequent short episodes of arthritis/arthralgia over the years (Table 1). She denied recurrent episodes of fever (as well as cold-induced episodes), rash, or uveitis/keratitis. Three family 107 members (2<sup>nd</sup> generation), all in their late 30's or early 40's, were affected (patients II2, II4, 108 and II6). They suffered from symmetrical bilateral mild to severe hearing loss and were 109 hearing aid-dependent (Figure 2). In all cases, hearing impairment was initially diagnosed in 110 111 their early 20's, without additional pathognomonic systemic CAPS manifestations. One 112 patient (II6) reported a past episode of unilateral acute hearing loss that did not respond to 113 steroid treatment, another reported episodes of arthritis during childhood (II2), and the third 114 sibling (II4) reported PFAPA-like episodes during childhood. Baseline inflammatory markers 115 were mostly within the normal range in these four patients, except for patient I4 (minimally elevated CRP) and patient II2 (slightly elevated SAA) (Table 2). 116

In contrast to the above 1<sup>st</sup> and 2<sup>nd</sup> generation carriers, who all suffered from 117 prolonged and severe SNHL, most of the 3<sup>rd</sup> generation carriers (15 or younger) had normal 118 hearing function (Supplemental Figure 1). Out of the nine known 3<sup>rd</sup> generation carriers, only 119 three children suffered from hearing loss (patients III2, III4, and III5) (Figure 2 and 120 121 Supplemental Figure 1C-D). Two suffered bilateral progressive SNHL; one, who initially presented with normal hearing function, was diagnosed with acute unilateral sensorineural 122 hearing deterioration during the study period (patients III4, III5, and III2, respectively). It 123 124 should be emphasized that all three children were initially diagnosed through annual auditory tests conducted considering the family history rather than due to any complaint of hearing 125 loss at the time. No other typical CAPS signs or symptoms were present. However, both 126 127 patients III4 and III5 (proband's siblings) reported PFAPA-like episodes that resolved in the 128 first grade. Inflammatory markers were within normal range except for minimally elevated 129 CRP in patient III4, and mildly elevated SAA in patient III2. It should be noted that during the initial asymptomatic period, SAA levels were within normal limits; they increased in 130 131 parallel to the rapid deterioration in her hearing function.

High-resolution MRI of the temporal bones were performed on all affected family
members excluding the grandmother (due to technical constraints), with no signs of cochlear
inflammation in the late gadolinium enhancement phase.

## 136 Earlier detection of SNHL in ultra-high frequencies auditory evaluation

137 All but one affected subject suffered from progressive bilateral SNHL with a down-138 sloping audiometric configuration and gradual deterioration over the years (Figure 2). The 139 SNHL pattern varied among patients, though most suffered symmetric hearing loss 140 (Supplemental Figure 1B). Two of these subjects (patients I4 and II6) also reported past 141 episodes of unilateral acute SNHL, which had been treated with oral steroids. One of them 142 reported partial improvement (I4). Over the course of the study, patient III2, a seven-year-old 143 female who initially presented with normal hearing function, suffered from acute 144 sensorineural hearing deterioration in her right ear that solely involved the high-ultrahigh 145 ranges (Figure 2). She was diagnosed in her routine semiannual checkup which included these frequency ranges. Patient I4 suffered from bilateral hearing deterioration over the years 146 147 (Figure 2) until the left ear reached profound SNHL and required cochlear implantation. Age-148 eligible carriers (three symptomatic and two asymptomatic children ages 6-12) ultra-high frequencies (8KHz–16KHz) were also assessed. In all cases, the hearing deterioration was 149 150 observed in the high and ultrahigh frequencies earlier than at the low frequencies (Figure 2). 151 Pure-tone audiometry did not reveal a significant air-bone gap in any of the affected 152 individuals.

## 153 Identification of a novel NLRP3 variant in all patients

154 Patient II6 from family 1 was the first in that family to undergo molecular analysis using the Otoscope Genetic Hearing Loss next-generation sequencing (NGS) gene panel (The 155 University of Iowa, Iowa City, Iowa), including 133 genes related to hearing loss. A 156 157 heterozygous novel variant of unknown significance NM\_001079821.3:c.1784G>A p.Ser595Asn (also known as NM\_001079821:c.1790G>A, p.Ser597Asn) was reported on 158 exon 5 (coding exon 3) of the NLRP3 gene (Figure 1B). It was predicted to result in a 159 160 missense substitution. The genomic position does not correspond with a known domain in the 161 NLRP3 protein (Figure 1B). However, a pathogenic variant at the same amino acid position (1783A>G p.Ser595Gly) related to CINCA syndrome was reported [11,12]. 162

In the unrelated Family 2, patient 2.1 was diagnosed with Muckle-Wells Syndrome, based on a classical clinical presentation and genetic results. An auto-inflammatory syndromes panel (Invitae Corporation, San Francisco, California) revealed a heterozygous likely pathogenic variant c.1218G>C, p.Met406Ile in NLRP3 (NM\_001079821.3) and a heterozygous variant of uncertain clinical significance in NCF2. Following parental segregation testing the variant in NLRP3 was found to be de-novo. The NLRP3 variant is located in the NACHT domain (exon 5).

It should be noted that in family 1a the father (II1) of the proband suffered from earlyonset hearing loss (non-SNHL). The hearing loss gene panel did not reveal variants in his
NLRP3 gene.

173

# NM\_001079821:c.1790G>A variant carriers present functional NLRP3 inflammasome hyper activation *ex-vivo*

177 In order to assess whether NM\_001079821:c.1790G>A, p.Ser597Asn NLRP3 variant results 178 in inflammasome hyperactivity, we measured the levels of IL-1 $\beta$  secretion of peripheral-179 blood mononuclear cells (PBMCs) isolated from our patients, in response to priming signal 180 alone (LPS or LPS+CaCl<sub>2</sub>) and in comparison to healthy controls. For technical reasons 181 (patient recruitment to the clinic), we conducted several independent cycles of the 182 experiment. In each cycle, we isolated PBMCs from both NLRP3 variation carriers 183 (c.1790G>A, p.Ser597Asn) and healthy generation-matched family members as controls. 184 Baseline IL-1 $\beta$  secretion levels (none treated) were comparable among all subjects. 185 Stimulation with LPS or LPS+CaCl2, resulted in higher IL-1ß secretion from NLRP3 186 variation carriers PBMCs compared to healthy subjects (Figure 3). The specificity of these 187 results to the NLRP3 inflammasome activation was confirmed by using the specific NLRP3 inhibitor, MCC950, or the specific caspase-1 inhibitor, VX-765. The addition of these 188 189 inhibitors to PBMCs prior to their priming by LPS+CaCl2 resulted in the reduction of elevated IL-1ß secretion in all subjects except of one (Figure 3B, C). The control, Muckle-190 Wells pediatric patient with a known pathogenic variant in NLRP3 (NM 004895.4 191 c.1224G>C (p.Met408Ile), showed similar results (Figure 3D). Finally, these results were 192 further statistically confirmed by pooling the three independent experiments and calculating 193 194 the fold of change (FC) of IL-1 $\beta$  secretion between each treatment to the non-treated PBMCs 195 (Figure 3E).

196 To complement IL-1 $\beta$  secretion measurement, we analyzed the expression and 197 cleavage of several NLRP3 inflammasome activation hallmarks: caspase-1, GSDMD, and IL-198 1β using immunoblot and specific antibodies. As can be seen in Figure 3G, pro-caspase-1, 199 pro-IL-1β, and full-length GSDMD were detected in the PBMCs of NLRP3 variation carrier 200 (subject I4) prior to LPS stimulation whilst remaining at undetected levels in the healthy 201 control (subject no.2). Furthermore, in agreement with IL-1 $\beta$  secretion phenotype, GSDMD 202 and caspase-1 in NLRP3 variation carrier PBMCs were detected in their activated (cleaved) 203 state (Figure 3D). Overall, these ex-vivo functional results suggest that c.1790G>A, 204 p.Ser597Asn is a gain-of-function mutation that results in a constitutively unique semi-205 activated basal state of the NLRP3 inflammasome.

206

## 207 Substantial hearing improvement in response to IL-1R antagonist treatment (Anakinra)

208 The clinical presentation, family segregation of the novel variant, and evidence of 209 inflammasome hyper-activation in the above *ex-vivo* functional studies suggest that the novel variant 001079821:c.1790G>A,p.Ser597Asn is a pathogenic gain-of-function mutation-210 211 causing atypical CAPS phenotype, according to the Eurofever classification criteria [13]. 212 Thus, we decided to treat the affected patients with an interleukin-1 receptor antagonist (IL-213 1Ra) drug, which blocks IL-1 $\beta$  activity. Therapy with IL-1Ra (Anakinra) was consequently 214 administered at an initial dose of 3 mg/kg (up to 100 mg) daily. Clinical follow-up included 215 clinical and hearing assessment as well as the measurement of inflammatory markers 1-3 216 months post-treatment initiation (Tables 2, 3). Audiometry reassessment was conducted one

217 and three months after treatment initiation. The three affected children showed rapid and near-complete reversal of hearing impairment, and returned to near-normal hearing function 218 within 1-3 months (Figure 4). Among the three 2<sup>nd</sup> generation subjects, we observed minimal 219 asymmetrical improvement in hearing function (Figure 5). Although the grandmother (patient 220 221 I4) with the cochlear implant did not report any improvement in hearing function, she did 222 report a resolution of arthralgia within two weeks of treatment initiation. In addition, all her 223 initially slightly elevated inflammatory markers returned to normal within one month of 224 treatment (Table 2.).

- 225 No severe adverse reactions to Anakinra were reported.
- 226

# 227 Discussion

Gain-of-function mutations in the NLRP3 gene led to hyper-activation of the NLRP3 inflammasome, resulting in excessive secretion of inflammatory cytokines such as IL-1 $\beta$  and IL-18. Clinically these mutations cause a spectrum of autosomal-dominant systemic autoinflammatory diseases known as CAPS/NLRP3-AIDs. In addition to the three classical clinical subtypes of CAPS (NOMID, MWS, and FCAS), there have been a few reports of NLRP3 missense variants associated with progressive sensorineural hearing loss as the primary/sole clinical manifestation [5,6,14].

235 In this study, we presented family members spanning three generations with a novel missense variant in the NLRP3 gene of unknown significance (NM 001079821:c.1790G>A, 236 237 p.Ser597Asn), with clinical features inconsistent with classical CAPS (i.e., past history of 238 PFAPA, sparse episodes of isolated fever, and nonspecific past history of arthralgia/arthritis). 239 Even though they did not meet the classification criteria for CAPS [13], the familial 240 genotype-phenotype segregation and potentially treatable hearing loss (autosomal dominant 241 progressive/rapid/mixed SNHL) led us to explore the suspected diagnosis of atypical CAPS. 242 Thus, in the hope of establishing the suspected diagnosis and enabling prompt initiation of 243 appropriate anti-IL-1 therapy, we conducted further clinical, imaging, and functional 244 inflammasome assessment.

245 Autosomal dominant progressive SNHL initially affected the high and ultrahigh frequency range (as seen in pediatric patients III2 and III4) and progressed to severe 246 247 impairment involving lower frequencies also in adult patients (Figure 2). In addition to the typical CAPS-associated bilateral progressive deterioration [15], some subjects suffered from 248 249 an atypical pattern of acute unilateral hearing loss (I4 and II6) (Figure 2). In the course of this 250 study, subject III2, a 5-10-year-old female who initially presented normal hearing function, 251 suffered from unilateral rapid sensorineural hearing deterioration that involved only the high-252 ultrahigh ranges (Figure 2). It should be notes that she had no auditory complaint s and was 253 diagnosed in her routine semiannual checkup which included these frequency ranges. To the 254 best of our knowledge, this is the first report of isolated acute hearing loss among CAPS 255 patients. Furthermore, the prompt initiation of Anakinra treatment in this patient, which led to 256 nearly complete resolution of SNHL (Figure 4), highlights the importance of both the routine 257 auditory evaluation of the high-ultrahigh ranges and rapid anti-IL-1 intervention treatment.

258 Interestingly, although the affected adults reported hearing impairment onset in their 259 early 20's, early symptomatic and asymptomatic changes in the high and ultrahigh-frequency 260 ranges were detected among the affected children as early as five years of age (Figure 2F-H). 261 This could be explained either by phenotypic progression over generations, increased awareness of hearing impairment among family members, or merely thanks to early detection 262 263 in semiannual hearing function tests starting from infancy that specifically included the high 264 and ultrahigh-frequency ranges. Nevertheless, regardless of the reason for this early 265 detection, this further supports the importance of adding these frequency ranges to the regular 266 auditory evaluation of these patients.

In addition to hearing impairment, further clinical evaluation of known carriers revealed a high prevalence of PFAPA in childhood among 4/13 carriers. This is an interesting finding, as although the pathogenesis of PFAPA syndrome is unknown, it has previously been linked to inflammasome hyper-activation [16].

Surprisingly, a magnetic resonance imaging (MRI) of the temporal bone did not reveal any signs of cochlear inflammation among affected family members. However, it should be noted that the grandmother (I4) did not complete an MRI due to cochlear implant incompatibility. In addition, as recently described [17], cochlear MRI may be normal in some CAPS patients with SNHL and is considered a positive predictive factor for clinical response to Anakinra treatment.

As described, in order to further establish the diagnosis, we conducted functional assessment of the NLRP3 inflammasome activity in PBMCs of carriers vs. healthy family members. As expected, secreted IL-1 $\beta$  levels and cleavage of GSDMD and caspase-1 were substantially and significantly higher among carriers vs. healthy controls following priming without the secondary and specific activation of the NLRP3 inflammasome. These results are consistent with the dogma that in cases of gain-of-function mutations in NLR as NLRP3, IL-1 $\beta$  secretion can be induced by priming signals such as LPS.[18,19]

The response to Anakinra treatment was dramatic, especially among the 3<sup>rd</sup> generation 284 pediatric patients. The three affected children showed near-complete reversal of hearing 285 286 impairment and returned to near normal hearing function within 1-3 months (Figures 4, 6). 287 Not surprisingly, the grandmother (I4), who presented the most severe and prolonged 288 symptoms, did not report improvement in hearing function, probably as a result of 289 irreversible cochlear damage on the right and the presence of the cochlear implant on the left. However, she did report a complete resolution of arthralgia within two weeks, and 290 inflammatory markers normalized within a month of treatment. 2<sup>nd</sup> generation patients (II2, 291 II4, and II6) who suffered from severe and prolonged hearing impairment (threshold below 292 293 60dB in some frequencies) (Figures 2C-E) still gained an overall slight improvement in hearing function (Figures 5-6). Although this could be a result of irreversible cochlear 294 295 damage after years of untreated cochlear inflammation, it could also be explained by the 296 relatively low initial Anakinra dosage (100 ng per day). For this reason, we are currently 297 considering increasing the daily dosage. In line with our observation, a recent study [17] 298 categorized seventeen families diagnosed with either CAPS or atypical CAPS according to 299 the severity of hearing impairment, MRI findings/absence of evidence of cochlear

inflammation, and evidence of NLRP3 hyper-activation (according to an in vitro LPS
 stimulation test). They suggested that a hearing function threshold below 60dB prior to
 Anakinra (Anti-IL-1) treatment and cochlear enhancement on brain MRI are related to poor
 audiological prognosis and responsiveness to Anakinra therapy.

In summary, our findings highlight the crucial role of early diagnosis and treatment with an anti-IL-1 agent in reversing cochlear damage. Furthermore, our results suggest that high and ultrahigh frequency ranges should be included in the auditory assessment to enable early detection of subclinical SNHL. Finally, functional inflammasome assessment can establish the diagnosis in inconclusive cases.

## 310 Material and methods

## 311 **Patients**

312 A family of Jewish Ashkenazi descent initially presented with autosomal dominant 313 bilateral SNHL with a progressive/rapid/mixed deterioration pattern. The hearing impairment 314 initially affected high/ultra-high frequencies as an isolated presentation or was accompanied 315 by nonspecific systemic signs and symptoms inconsistent with typical CAPS (i.e., sporadic 316 episodes of fever, arthritis/arthralgia, or PFAPA (periodic fever, aphthous stomatitis, 317 pharyngitis, adenitis)). All SNHL family members were carriers of a novel missense mutation 318 in NLRP3 of unknown significance and did not fulfill CAPS classification criteria [13] 319 (Figure 1A, Table 1). We assessed ten known carriers spanning three generations who were found to be carriers of the NLRP3 variant, seven with impaired and three with normal hearing 320 321 function. Age at study initiation ranged from 2-70 years. The control group consisted of five 322 healthy family members who were matched by age group. Our study group also included one 323 unrelated 5-10-year-old patient (P 2.1) who presented with classical signs and symptoms of 324 Muckle-Wells and is a carrier of a known heterozygous pathogenic variant (NM\_004895.4) in NLRP3. This patient served as a positive control for inflammasome hyperactivation in the 325 326 study.

327

## 328 Clinical and genetic evaluation

329 Affected family members underwent clinical evaluation by a clinical rheumatologist, 330 otorhinolaryngologist, and a clinical geneticist. Medical records and past audiometry tests 331 were reviewed. Clinical evaluation and peripheral blood inflammatory markers were obtained 332 for all symptomatic patients before and after interleukin-1 receptor antagonist (IL-1Ra) 333 (anakinra) treatment initiation. Pure-tone audiometry was performed per test eligibility (age-334 dependent) on all known carriers, of whom seven were symptomatic (I4, II2, II4, II6, III2, 335 III4, III5). The ultra-high frequency range (8KHz - 16KHz) was also evaluated in patients 336 III2, III4, III5, III7, and III9. Follow-up audiometry was conducted on all treated patients.

High-resolution magnetic resonance imaging (MRI) scans of the temporal bones were performed with a Philips Ingenia 3 Tesla system (Philips Healthcare). The scans included an axial heavily T2 weighted sequence (DRIVE) and a T1 weighted sequence. Following the injection of Gadolinium-based contrast media, a 3D sequence (3D FLAIR or 3D T1 Dixon) was performed.

342

## 343 *Ex-vivo* functional assessment of NLRP3 inflammasome activity

344 Peripheral blood samples were drawn into an EDTA tube from a total of 15 subjects 345 (11 novel variant carriers, one Muckle-Wells patient, and three age-matched healthy family 346 members as controls). PBMCs were immediately isolated (up to two hours from collection) 347 as done previously [20]. See Supplementary Data for further details. Approximately  $10^5$ 348 PBMCs were seeded in each well of the 96 well plate and LPS was added to indicate wells 349 for three hours. Where indicated, caspase-1 inhibitor, Vx765, or NLRP3 inhibitor, MCC950, 350 were added 30 minutes prior to CaCl<sub>2</sub> addition. Cell supernatants and cell lysates were 351 collected three hours later for further analysis. Supernatants were analyzed for IL-1 $\beta$ 352 secretion using ELISA kit (Invitrogen Waltham, Massachusetts, USA). Cell lysates were

analyzed for cleaved human-IL-1 $\beta$ , cleaved caspase-1, and cleaved GSDMD using immunoblot and specific antibodies. See further details in supplementary data.

## 355 Statistics

356 Statistical comparisons in the *ex-vivo* experiments between the different treatments 357 were performed using multiple unpaired t-tests. A comparison of hearing before and after 358 Anakinra treatment was preform using RM two-way ANOVA. P values <0.05 were 359 considered statistically significant.

# 360 Data analysis

361 Data were calculated using GraphPad Prism 9, and details can be found in the figure 362 legends.

363

# 364 **Data availability statement**

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding

authors.

# 368

# 369 Ethics statement

All experiments in this study were reviewed and approved by the ethics committee (RMC0941-20) and performed according to the Declaration of Helsinki. Prospective and retrospective reviews of medical history, laboratory and imaging results, rheumatologic evaluations, and laboratory tests were performed after informed consent. Written informed consent was obtained from adult subjects and from both parents of minor subjects.

375

# 376 Author contributions

BM initiated and designed the study concept and coordinated the multidisciplinary assessment of patients; BM, CH, and GM designed the experiments; BM, and CH performed experiments; SM, RE, and HO performed the clinical hearing evaluation; KL performed the brain image analysis; KN, SE, and ON coordinated and conducted clinical-genetic assessments; AG, DR, LG, BM, and HL, performed the clinical evaluation and management; BM, wrote the original draft; All authors wrote and edited the manuscript. HL, and GM contributed to the study conception and design and supervised the work.

384

# 385 Funding

GM acknowledges funding from US-BSF grant #2017176, ISF grant #2174/22.

# 387 **Conflict of interest**

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

390

## 391 Acknowledgments

First and foremost, we would like to extend our thanks and appreciation to all family members who participated in this study. We would also like to express gratitude to our colleagues Ivona Aksentijevich, Kalpana Manthiram, and Amanda Ombrelo from the National Institute of Health; and Ziv Erlich from Tel Aviv University for their assistance throughout.

397

## **398 Contribution to the field statement**

399 Cryopyrin-associated periodic syndromes (CAPS) are a spectrum of rare auto-400 inflammatory diseases caused by gain-of-function mutations in the NLRP3 gene, resulting in 401 inflammasome hyper-activation and subsequent uncontrolled release of Interleukin-1 $\beta$  (IL-402 1β). Many patients with CAPS develop progressive sensorineural hearing loss (SNHL) due to 403 cochlear auto-inflammation, which in rare cases may be the sole or main manifestation. In 404 this study, we establish the suspected diagnosis of CAPS in a family presenting autosomal 405 dominant SNHL with progressive/acute deterioration and a novel missense variant in the 406 NLRP3 gene of unknown significance (NM 001079821:c.1790G>A, p.Ser597Asn), by 407 conducting ex-vivo functional assessment of the NLRP3 inflammasome. Subsequent 408 administration of anti-IL-1 therapy resulted in a substantial clinical improvement especially 409 among pediatric patients who exhibited near resolution of hearing impairment within a few 410 months of treatment. Our findings highlight the crucial role of early diagnosis and treatment 411 with an anti-IL-1 agent in reversing cochlear damage. Furthermore, our results suggest that high and ultrahigh frequency ranges need to be included in the auditory assessment to enable 412 early detection of subclinical SNHL. Finally, incorporating functional inflammasome 413 414 assessment as part of the clinical evaluation could establish the diagnosis in inconclusive 415 cases.

## 417 **<u>References</u>**

- 1. Schroder K, Tschopp J. The Inflammasomes. Cell. 2010;140:821–32.
- 419 2. Broide DH, Hoffman HM, Mueller JL, Broide DH. Mutation of a new gene encoding a
- 420 putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-
- 421 Wells syndrome. Nat Genet [Internet]. 2001 [cited 2021 Oct 4];29:301–5. Available from:
- 422 https://brmc.tdnetdiscover.com/results/mendeleycallback?token=ui.export.mendeley.f84a5b1
- 423 b-d635-42da-a44e-
- 424 5e813cdd9066&returnUrl=/discover/result?logSearchID=77717782&pubid=7156-
- 425 oai%3Apubmedcentral.nih.gov%3A4322000&pubid=7902-
- 426 info%3Adoi%2F10.1038%252Fng756&pubid=6057-medline%3A11687797
- 427 3. Hoffman HM, Booshehri L, Hoffman H. CAPS and NLRP3. J Clin Immunol [Internet].
- 4282019[cited2020Oct29];39:277–86.Availablefrom:429https://brmc.tdnetdiscover.com/results/mendeleycallback?token=ui.export.mendeley.ef50a8d
- 430 9-50fa-4bb2-bd54-
- 431 1e67a1880575&returnUrl=/discover/result?logSearchID=56293390&pubid=7109-
- 432 springer%3A10.1007%2Fs10875-019-00638-z&pubid=7902-
- 433 info%3Adoi%2F10.1007%252Fs10875-019-00638-z&pubid=6057-medline%3A31077002
- 434 4. Yamada S, Kita J, Shinmura D, Nakamura Y, Sahara S, Misawa K, et al. Update on
- 435 Findings about Sudden Sensorineural Hearing Loss and Insight into Its Pathogenesis. J Clin
- 436 Med. MDPI AG; 2022;11:6387.
- 437 5. Oziębło D, Leja ML, Jeznach A, Orzechowska M, Skirecki T, Więsik-Szewczyk E, et al.
- 438 Hearing Loss as the Main Clinical Presentation in NLRP3-Associated Autoinflammatory
- 439 Disease. Front Immunol. Frontiers Media S.A.; 2022;13.
- 6. Nakanishi H, Kawashima Y, Kurima K, Muskett JA, Kim HJ, Brewer CC, et al. Gradual
  Symmetric Progression of DFNA34 Hearing Loss Caused by an NLRP3 Mutation and
- 442 Cochlear Autoinflammation. Otology and Neurotology. 2018;39:e181–5.
- 443 7. Schroder K, Tschopp J. The Inflammasomes. Cell. Elsevier B.V.; 2010. p. 821–32.
- 8. Lamkanfi M, Dixit VM. Mechanisms and functions of inflammasomes. Cell. Elsevier
  B.V.; 2014. p. 1013–22.
- 9. Erlich Z, Shlomovitz I, Edry-Botzer L, Cohen H, Frank D, Wang H, et al. Macrophages,
  rather than DCs, are responsible for inflammasome activity in the GM-CSF BMDC model.
  Nat Immunol. Nature Research; 2019. p. 397–406.
- 10. He WT, Wan H, Hu L, Chen P, Wang X, Huang Z, et al. Gasdermin D is an executor of
  pyroptosis and required for interleukin-1β secretion. Cell Res. Nature Publishing Group;
  2015;25:1285–98.
- 452 11. Kanariou M, Dracou C, Spanou K, Möller J, Rösen-Wolff A, Schuster V, et al. Twenty
  453 year follow up of a patient with a new de-novo NLRP3 mutation (S595G) and CINCA
  454 syndrome. Klin Padiatr. 2009;221:379–81.

- 455 12. Li C, Tan X, Zhang J, Li S, Mo W, Han T, et al. Gene mutations and clinical phenotypes
- 456 in 15 Chinese children with cryopyrin-associated periodic syndrome (CAPS). Sci China Life
- 457 Sci. Science in China Press; 2017;60:1436–44.
- 458 13. Gattorno M, Hofer M, Federici S, Vanoni F, Bovis F, Aksentijevich I, et al. Classification
- 459 criteria for autoinflammatory recurrent fevers. Ann Rheum Dis. BMJ Publishing Group;460 2019;78:1025–32.
- 14. Nakanishi H, Prakash P, Ito T, Kim HJ, Brewer CC, Harrow D, et al. Genetic Hearing
  Loss Associated With Autoinflammation. Front Neurol. 2020;11:1–7.
- 15. Nakanishi H, Yamada S, Kita J, Shinmura D, Hosokawa K, Sahara S, et al. Auditory and
  Vestibular Characteristics of NLRP3 Inflammasome Related Autoinflammatory Disorders:
  Monogenic Hearing Loss Can Be Improved by Anti-interleukin-1 Therapy. Front Neurol.
  Frontiers Media S.A.; 2022.
- 467 16. Kolly L, Busso N, Von Scheven-Gete A, Bagnoud N, Moix I, Holzinger D, et al. Periodic 468 fever, aphthous stomatitis, pharyngitis, cervical adenitis syndrome is linked to dysregulated 469 monocyte IL-1β production. Journal of Allergy and Clinical Immunology. 2013;131:1635– 470 43.
- 471 17. Kim BJ, Kim YH, Lee S, Han JH, Lee S-Y, Seong J, et al. Otological aspects of NLRP3472 related autoinflammatory disorder focusing on the responsiveness to anakinra.
  473 Rheumatology. 2020;1–10.
- 18. Nakanishi H, Kawashima Y, Kurima K, Chae JJ, Ross AM, Pinto-Patarroyo G, et al.
  NLRP3 mutation and cochlear autoinflammation cause syndromic and nonsyndromic hearing
  loss DFNA34 responsive to anakinra therapy. Proc Natl Acad Sci U S A. 2017;114:E7766–
  75.
- 478 19. Masters SL, Gerlic M, Metcalf D, Preston S, Pellegrini M, O'Donnell JA, et al. NLRP1
  479 Inflammasome Activation Induces Pyroptosis of Hematopoietic Progenitor Cells. Immunity.
  480 2012;37:1009–23.
- 481 20. Cohen H, Baram N, Edry-Botzer L, Munitz A, Salomon D, Gerlic M. Vibrio pore-
- 482 forming leukocidin activates pyroptotic cell death via the NLRP3 inflammasome. Emerg
- 483 Microbes Infect. Taylor and Francis Ltd.; 2020;9:278–90.
- 484

487 Table 1. Clinical characteristics of family members with sensorineural hea	ring loss
--------------------------------------------------------------------------------	-----------

Subject	Age	Sex	Periodic fever	Musculoskeletal	Urticaria 1 Rash	Eye involvement	Cochlear Inflammation in MRI	Other***
I4	>70	F	No	Recurrent short episodes of arthritis/ arthralgia	No	No	Not conducted	Rheumatic fever with carditis, ITP*
II2	41-45	F	No	Recurrent short episodes of arthritis/ arthralgia as an adolescent post pharyngitis episode	No	No	No	Suspected Rheumatic fever as a child (no carditis)
II4	35-40	М	PFAPA** - like resolved	No	No	No	No	
II6	35-40	М	No	No	No	No	No	
III2	6-10	F	No	No	No	No	No	
III4	6-10	М	PFAPA- like resolved	No	No	No	No	
III5	10-15	F	PFAPA- like resolved	No	No	No	No	

\* ITP- Idiopathic Thrombocytopenic Purpura \*\* PFAPA- periodic fever, aphthous stomatitis, pharyngitis, adenitis \*\*\* Other autoimmune phenomena

	<u>Prio</u>	or to Anak	inra Treatr	<u>nent</u>	After 3 months of Anakinra Treatment			
Patient	WBC	ESR	CRP	SAA	WBC	ESR	CRP	SAA
I4	7.2	36	0.84	5.3	4.42	8	0.16	2.8
II2	7.54	28 (old)	0.56	22.7	5	24	< 0.05	4.7
II4	6.9	15	0.25	6.2	7.12	10*	0.09	Х
II6	7	12	0.52	5.5	7	5	0.07	Х
III2	11.13	19	0.26	4-12.6 **	7.88*	21*	0.43*	Х
III4	10.4	14	1.19	< 0.82	5.2	13	0.6	3
III5	6.6	15	0.64	3.3	5.71	5	< 0.05	1

## 489 Table 2. Inflammatory markers levels pre- and post- Anakinra

\* 1 month after Anakinra initiation \*\* Original levels of SAA were undetectable. However, SAA levels were measured and elevated during sudden hearing loss episode. White blood cells (WBC) K/micl, ESR- mm/1hr, CRP- C reactive protein mg/dL, SAA - Serum Amyloid A mg/l (range 0.0-6.4)

491	Table 3. SNHL	features and	response to	Anakinra	treatment
-----	---------------	--------------	-------------	----------	-----------

Patient	Description	Episode of Unilateral Hearing Loss	Age At Hearing Impairment Onset (years)	Age at Treatment Initiation	Duration of Hearing Impairment Prior to Anakinra Initiation (years)	Response to Treatment (~ 3 months)
I4	Severe bilateral progressive SNHL	Yes	16-20	>70	~50	No improvement
II2	Severe-moderate bilateral progressive SNHL	No	16-20	41-45	~20	Mild improvement (asymmetrical)
II4	Severe-moderate bilateral progressive SNHL	No	16-20	35-40	~20	Mild improvement (asymmetrical)
II6	Severe-moderate bilateral progressive SNHL	Yes	16-20	35-40	~20	Minimal-no improvement (asymmetrical)
III2	Moderate unilateral sudden HL	Yes	6-10	6-10	0	Near-complete resolution of HL
III4	Mild-moderate bilateral progressive SNHL	No	6-10	6-10	3	Complete resolution of HL
1115	Moderate-severe bilateral progressive SNHL	No	6-10	11-15	6	Near-complete resolution of HL

HL- Hearing Loss, SNHL- Sensorineural Hearing Loss

#### 493 Figures



494

#### 495 Figure 1. Family Pedigree and genetic information

496 (A) Pedigree of the investigated family. Subjects with autosomal dominant hearing loss are 497 represented in green. Asymptomatic carriers and healthy family members are represented in 498 white. Carrier status is indicated below each subject. The proband (III1) is indicated by an 499 arrow. Pedigree was created using the Invitae family history tool (Invitae Corporation, San 500 Francisco, California). (B) Schematic view of the NLRP3 gene: Figure adapted from UCSC genome browser, based on transcript NM\_001079821.3. The figure shows only coding exons. 501 502 Domain locations according to UniProt track (https://www.uniprot.org/) in UCSC genome browser (https://genome.ucsc.edu/). Variants p.Ser595Asn and p.Met406Ile, reported in this 503 paper, are colored in red and blue, respectively. In black, previously reported variants 504 505 p.Ser624Arg and p.Arg918Pro are associated with syndromic/nonsyndromic hearing loss as the primary presentation of CAPS [5,18] 506





508

Air conduction hearing thresholds in the better performing ear (aside from patient III4 who suffered from unilateral HL) depicting hearing deterioration over time, prior to Anakinra treatment. Patient identification number is shown on the top of each panel. (A) The Y axis represents hearing threshold level [dB] and the X axis tested frequency (kHz). (B-H) The Y axis represents hearing threshold level [dB] and the X axis age of patient (years). Each graph (in different colors) represents a different tested frequency (kHz).





# 517 Figure 3 Ex-vivo functional assessment of NLRP3 activity

Approximately 10^5 PBMCs were seeded into 96-wells plate (D1-D4) or 10^6 PBMCs were seeded into 24-wells plate (D5-D16). Indicated wells were primed with lipopolysaccharides (LPS) (1  $\mu$ g/mL) 3 hours prior to the experiment. Where indicated, MCC950 (2  $\mu$ M) or Vx765 (25  $\mu$ M) were added 30 minutes prior to the addition of CaCl<sub>2</sub> (1 mM). (A) Cell

522 supernatants from each experiment described above were collected 3 hours after  $CaCl_2$ 523 addition or 6 hours after LPS addition. IL-1 $\beta$  secretion was measured using commercial 524 ELISA kit. (B) Fold of change (FC) of IL-1 $\beta$  secreted from NLRP3 variant carriers PBMCs 525 compared to internal healthy control of the same experiment. (C) Change in IL-1 $\beta$  secretion 526 before and after MCC950 or Vx756 addition. (D) Caspase-1, gasdermin D (GSDMD), and IL-1 $\beta$  were detected in PBMC lysate by immunoblotting. Statistical comparisons in (B) 527 between the NLRP3 variant carriers and healthy controls, were performed using multiple 528 529 unpaired t-tests, P < 0.05. In (**D**) arrows denote the expected.

530 531





533 Figure 4. Anakinra restores hearing loss in pediatric symptomatic patients

Air conduction hearing thresholds depicting dynamics in hearing function over time, in response to Anakinra treatment. Patient identification number is shown on the top of each panel. The Y axis represents hearing threshold level [dB] and the X axis time from treatment initiation (months). Each graph (in different colors) represents a different tested frequency (kHz).







Air conduction hearing thresholds depicting dynamics in hearing function over time, in response to Anakinra treatment. Patient identification number is shown on the top of each panel. The Y axis represents hearing threshold level [dB] and the X axis time from treatment initiation (months). Each graph (in different colors) represents a different tested frequency (kHz).



548

# 549 Figure 6. Comparison of hearing loss Anakinra restoration in adults and pediatric 550 symptomatic patients

Air conduction hearing thresholds representing dynamics of hearing function one month after initiation of Anakinra treatment in  $2^{nd}$  (N=3, both ears were tested) and  $3^{rd}$  (N=3, one ear, the affected ear was tested) generation patients (left and right panel, respectively). Generation specified on the top of each panel. The Y axis represents the hearing threshold level [dB], and the X axis tests frequency (kHz). Averages of pre-treatment is represented in red and posttreatment in blue. In the Statistical comparisons between the pre- and post-treatment were performed using two-way ANOVA (Fisher's LSD test), Significant (*P*<0.05) is shown.

#### 559 Supplemental material

#### 560 Peripheral blood mononuclear cells (PBMCs) isolation

561 PBMCs were isolated from peripheral venous blood samples freshly drawn from subjects 1-562 16. Briefly, 10-30 ml of peripheral blood were collected and loaded on Histopaque-1077 563 (Sigma Aldrich 10771). Cells were centrifuged for 30 min at 400 g at 24°C. Cells from the 564 interphase were collected and washed with PBS. Samples of the cells were then stained for 565 flow cytometry to determine the percentage and concentration of monocytes, before they 566 were seeded in a 96-wells plate or a 24-wells plate at a final concentration of 10<sup>6</sup> 567 monocytes/ml, in DMEM supplemented with 10% heat-inactivated fetal bovine serum (FBS) 568 (Gibco, 10270106). After 18 h, the wells were washed three times to remove non-adherent 569 cells and medium was replaced with DMEM supplemented with 1% FBS. Cells were treated 570 with lug/mL ultrapure LPS. After 3 hours of LPS treatment, 2 ug/mL MCC950 or 25 µM 571 Vx765 were added to selected wells for 30 minutes prior to adding 1mM CaCl2 for 3 hours. 572 After 3 hours cell supernatants and cell lysates were collected for further analysis by ELISA 573 or immunoblot, respectively. Experiments were performed according to the guidelines of the 574 Institute's Helsinki Ethics Committee.

#### 575 Immunoblot analysis of proteins

576 Cells were collected and centrifuged for five minutes at 400xg in order to separate them from the supernatant. Next, the cells were lysed by using RIPA buffer in the presence of protease 577 578 inhibitors at 4°C for 15 min. Lysed cells were loaded onto any kD gradient Criterion TGX-579 Free precast gels (Bio-Rad, Hercules, California, USA). Proteins were transferred onto a 580 nitrocellulose membrane (Bio-Rad), and Ponceau S staining was performed routinely to evaluate the loading accuracy. Membranes were blocked with 5% (w/v) skim milk in TBS for 581 582 1-2 h, and then probed overnight with primary antibodies (all diluted 1:1000, unless noted 583 otherwise): pro and cleaved human-IL-1  $\beta$  (R&D, AF-201-NA), pro and cleaved human 584 caspase-1 (Merck, 06-503-I), and pro and cleaved human-GSDMD (abcam, ab210070). 585 Relevant horseradish peroxidase-conjugated secondary antibodies were applied for at least 1 586 hour. Membranes were washed between antibody incubations four times in TBS containing 587 0.1% (v/v) Tween 20 (TBST). Antibodies were diluted in TBST containing 5% skim milk. 588 Immunoblots were developed using an ECL kit (Bio-Rad) in an ODYSSEY Fc (Li-COR, 589 Lincoln, Nebraska USA) equipped with Image Lab software. All images were cropped for 590 presentation. Full-size images will be presented upon request.

#### 591 **Reagents**

592 Unless stated otherwise, all cell culture reagents were purchased from Biological 593 Industries, Beit-Haemek, Israel. Lipopolysaccharides (LPS) of Escherichia coli O111:B4 594 were purchased from Sigma-Aldrich (#L3024, Munich, Germany). Vx765 and MCC950 and 595 ELISA kit were purchased from Invitrogen (Waltham, Massachusetts, USA). HRP-596 conjugated secondary antibodies were purchased from Jackson ImmunoResearch Labs (West 597 Grove, PA, USA).

## 599 Supplemental Figures

600





Pooled same-generation auditory phenotypes based on generation and hearing loss status are
stated on the top of each panel. Although hearing loss severity per tested frequency varied
among patients, overall, the high-ultrahigh hearing range is most severely affected (panels A,
D).